Madrigal在2025年的Q4损失2.57美元, 尽管收入猛增210%, Madrigal lost $2.57/share in Q4 2025 despite revenue surging 210%, spurring an 11% stock drop.

Madrigal制药公司报告说,2025年第四季度的收入为每股损失2.57美元,估计损失为2,500万美元,尽管收入猛增210%,达到3.2108亿美元,超过了预测。 Madrigal Pharmaceuticals reported fourth-quarter 2025 earnings of $2.57 per share in loss, missing estimates, though revenue surged 210% to $321.08 million, exceeding forecasts. 该公司的净负差为39.04%,股本回报率为41.50%,由于先前的交易,研发和SG&A费用很高。 The company posted a negative net margin of 39.04% and return on equity of 41.50%, with R&D and SG&A expenses high due to prior deals. 尽管现金状况为9.89亿美元,预计2026年的销售增长幅度高达30%,但在内幕销售和投资者的担忧下,股票下跌了11%,降至453.94美元。 Despite a $989 million cash position and projected 2026 sales growth in the high 30% range, shares fell 11% to $453.94 amid insider selling and investor concerns. 该股票的市场上限为103.1亿美元,中度购买评级和663.86美元价格目标。 The stock has a market cap of $10.31 billion, with a moderate buy rating and $663.86 price target.